CAD 0.31
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 2.38 Million CAD | 94.92% |
2022 | 1.22 Million CAD | 69.24% |
2021 | 721.6 Thousand CAD | 69.74% |
2020 | 425.13 Thousand CAD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 2.13 Million CAD | -10.46% |
2023 Q3 | 1.86 Million CAD | 12.72% |
2023 FY | 2.38 Million CAD | 94.92% |
2023 Q1 | 1.46 Million CAD | 19.59% |
2023 Q4 | 2.38 Million CAD | 27.74% |
2023 Q2 | 1.65 Million CAD | 13.2% |
2022 Q3 | 884.31 Thousand CAD | 14.08% |
2022 FY | 1.22 Million CAD | 69.24% |
2022 Q4 | 1.22 Million CAD | 38.1% |
2022 Q2 | 775.18 Thousand CAD | -36.53% |
2022 Q1 | 1.22 Million CAD | 69.24% |
2021 FY | 721.6 Thousand CAD | 69.74% |
2021 Q3 | 731.36 Thousand CAD | 0.0% |
2021 Q4 | 721.6 Thousand CAD | -1.33% |
2020 FY | 425.13 Thousand CAD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
AI/ML Innovations Inc. | 1.53 Million CAD | -54.608% |
Diagnamed Holdings Corp. | 426.38 Thousand CAD | -458.287% |
Pangenomic Health Inc. | 2.21 Million CAD | -7.416% |
nDatalyze Corp. | 38.26 Thousand CAD | -6121.704% |
Treatment.Com International Inc. | 1.47 Million CAD | -61.127% |